Post Transplant Outcome of a Multicenter Phase II Study of Brentuximab Vedotin As First Line Salvage Therapy in Relapsed/Refractory HL Prior to AHCTRobert Chen, Stephen J. Forman, Joycelynne Palmer et al.|Blood|2015Cited by 13
Influence of donor KIR genotypes on reduced relapse risk in acute myelogenous leukemia after hematopoietic stem cell transplantation in patients with CMV reactivationRyotaro Nakamura, Anthony S. Stein, Ketevan Gendzekhadze et al.|Leukemia Research|2019Cited by 12
Randomized placebo-controlled, double-blind clinical trial of nanoemulsion curcumin in women with aromatase inhibitor-induced arthropathy: an Alliance/NCORP pilot trialMaryam B. Lustberg, Chidimma Kalu, Mina S. Sedrak et al.|Breast Cancer Research and Treatment|2024Cited by 12
Reduced Relapse Risk in Acute Myelogenous Leukemia (AML) after Allogeneic Hematopoietic Stem Cell Transplantation (HCT) in Patients Who Experienced CMV Reactivation: Influence of Donor KIR GenotypesAnthony S. Stein, Ryotaro Nakamura, Ketevan Gendzekhadze et al.|Blood|2014Cited by 1
Impact of CYP3A5/CYP2C19 Pharmacogenetics on Clinical Outcomes after Allogeneic Hematopoietic Stem Cell Transplantation (HCT) Using Tacrolimus/Sirolimus (Tac/Sir) as Graft Versus Host Disease (GVHD) ProphylaxisSamer K. Khaled, Ryotaro Nakamura, Ni‐Chun Tsai et al.|Transplantation and Cellular Therapy|2017Cited by 0